MUMBAI (Reuters) - Daiichi Sankyo's $4.6 billion bid for control of India's Ranbaxy Laboratories Ltd could be the trigger for foreign pharmaceutical companies to step up the hunt for low-cost Indian drug makers for fear of being left behind. Global ...